Articles tagged with Cancer Medication
Researchers at the University of Iowa have discovered a way to improve cancer immunotherapy by directing specific types of white blood cells to kill cancer cells. By using CpG ODN agents, doctors can gear up natural killer cells and granulocytes to work with antibodies to target cancer cells more effectively.
A new combination cancer-killing drug regimen has shown promising results in extending patient survival, with 16% tumor shrinkage and 35% stable disease progression after six months. The orally administered treatment has been well-tolerated and offers a more convenient option for patients compared to traditional IV chemotherapy.
Researchers identify unsuspected gene C/EBP-beta as key mediator of cyclin D1 action in human tumors. The technique combines data from the Global Cancer Map and gene chips to pinpoint gene interactions that lead to cancer.
Researchers found that a paclitaxel combination improved median and long-term survival rates for patients with early-stage SCLC. The treatment also reduced side effects compared to standard chemotherapy.
Consuming phytoestrogens found in plant foods like soy is associated with a reduced risk of endometrial cancer. Imiquimod has been shown to induce apoptosis in skin cancer cells, while an integrin polymorphism may increase cancer progression. The study on breast cancer survivors also found increased numbers of circulating T lymphocytes.
Research suggests that a mutation in a tyrosine kinase receptor gene, when combined with aml1-eto gene mutation, can cause acute myeloid leukemia in mice. This discovery raises the possibility of new treatments targeting these genes to control the disease.
A recent study confirms oxaliplatin's safety in treating advanced colorectal cancer, with low rates of high-grade gastrointestinal side effects. The treatment regimen, combined with fluorouracil and leucovorin, showed improved results in patients who had previously failed first-line chemotherapy.
A Phase III trial found that pemetrexed and cisplatin significantly improved one-year survival rates for mesothelioma patients to 56.5%, compared to 41.9% for those receiving only cisplatin.
CYC202 demonstrates significant cancer cell death, with 54% of patients testing positive for apoptosis following single agent treatment. Seven patients experienced long-lasting tumour stabilisation in Phase I trials, showcasing potential for selective treatment based on genetic profiles.
Researchers at Wake Forest University Baptist Medical Center have found that oxaliplatin can effectively treat human cancers resistant to other platinum-based therapies. The drug works differently than cisplatin and shows promise in combination with radiation therapy for patients with earlier stages of rectal cancer.
Researchers have developed a new generation of targeted cancer therapies using bispecific antibodies that target multiple proteins in cancer cells, increasing radiation sensitivity and specificity. The therapy is expected to improve treatment outcomes for patients with breast and ovarian cancers.
A national study found that 43% of patients reported nausea on the day of treatment, and 73% experienced nausea one or more days later. Delayed nausea is a significant problem, affecting twice as many patients who felt ill in the following days compared to those who felt queasy initially.
A randomized clinical trial of over 500 women with primary breast cancer found no significant improvement in disease-free survival or overall survival with high-dose chemotherapy and stem cell transplantation. However, time to recurrence was longer for patients who received the treatment.
A phase II multicenter collaborative study found that Velcade significantly reduced disease in 67% of patients with advanced multiple myeloma, with some achieving complete or near-complete responses. The drug has shown great potential to improve patient outcomes in this incurable disease.
A phase 2 clinical trial found that bortezomib responded positively in 193 relapsed patients, including seven with undetectable myeloma protein and 12 with detectable protein only with immunofixation. The results confirmed significant clinical benefits from therapy.
A new study by UT Southwestern finds that finasteride effectively reduces prostate cancer risk and improves symptoms in men with benign prostatic hyperplasia. The drug, already used to treat BPH, works by inhibiting the conversion of testosterone to dihydrotestosterone, which is involved in prostate cancer development.
Dr. Barry Siegel is being recognized for his pioneering work in nuclear medicine, including the use of positron emission tomography (PET) in cancer detection and tumor staging. With over 220 publications to his credit, Dr. Siegel's contributions have significantly impacted the field of nuclear medicine.
The European Society for Medical Oncology (ESMO) presented a new drug, ET743, which has shown promising results in treating advanced ovarian cancer. In a clinical trial, the drug reduced tumors in 47% of patients, with some experiencing complete responses.
Susan Bane's research focuses on understanding how anticancer drugs like Taxol interact with tubulin at the molecular level. The study of these interactions could pave the way for the development of more effective next-generation cancer drugs, potentially with improved administration and reduced resistance.
Drs. Chang and Moore were awarded the Mott Prize for their discovery of KSHV, a virus linked to Kaposi's sarcoma, the most common malignancy in AIDS patients. Their work has opened new areas in cancer research and will continue to use innovative techniques to understand KSHV's impact on cancer.
Researchers discovered a core set of essential genes that universally activate in human cancer, regardless of tissue origin. The findings suggest these genes are prime targets for new cancer-fighting drugs.
The study found that BAC proliferation correlated with HER2 but not EGFR expression, suggesting a potential role for combination therapies. Researchers hope to launch a clinical trial of HER2- and EGFR-blocker combination therapy in the treatment of BAC.
Bruce Lipshutz's patented method uses transition metal catalysts to produce CoQ10 efficiently, targeting cancer, Parkinson's, and Huntington's diseases. The process reduces costs by using inexpensive ingredients and minimizing production steps.
A recent study found that paroxetine significantly reduced the frequency of hot flashes in menopausal women by 64.6%, with up to 30% experiencing no flashes after six weeks. The medication worked by inhibiting serotonin reuptake, a natural chemical modulating mood and temperature control.
The use of generic drugs led to a slowdown in prescription drug spending during the first quarter, with a 3.2% reduction in dollar outlay. Physicians responded positively to safety warnings and modified patient therapy as a result, with 38% changing or modifying their treatment.
A new study found that tamoxifen is effective in reducing breast cancer cell proliferation at lower doses, with decreases in biomarkers associated with cardiovascular disease and blood clots. The results support a potential dose reduction for tamoxifen therapy without compromising its effectiveness.
Researchers at Cedars-Sinai Medical Center developed a molecular test that identified a panel of genes correlating with tumor response to gefitinib, a drug approved for shrinking tumors in advanced lung cancer. The study found distinct patterns of gene expression linked to patient responses or lack thereof.
An early clinical trial at Cedars-Sinai Medical Center shows 2C4 effectively shrank tumors in several types of cancer, targeting a common growth signaling pathway. Eighteen out of twenty-one patients responded to treatment, with some achieving partial remission and stabilizing disease for over a year.
Researchers found that a standard dose of Gleevec is as effective and less toxic than doubling the dose for treating GIST. The study confirms that Imatinib is remarkably sensitive to Gleevec and is the best therapy for treating these tumors, even with metastasis.
Bevacizumab significantly extends survival time for metastatic colorectal cancer patients by shrinking tumors and inhibiting tumor growth. The study showed a median survival increase of five months compared to standard chemotherapy alone, with significant delays in cancer progression.
USC researchers have identified a protein fragment, PEP, that can increase the effectiveness of chemotherapy drugs against tumors. By making tumor blood vessels more permeable, PEP allows for better drug uptake and increased chemotherapy efficacy.
Researchers discovered a novel way to defeat Gleevec-resistant cancer using a second drug that targets the tyrosine kinase enzyme. This proof-of-principle shows promise for treating patients with a range of cancers.
Researchers discover that ovarian tumor cells can 'switch back' to a normal state, making them vulnerable to chemotherapy. This finding represents a crucial step toward the discovery of new anti-cancer drugs.
A study of 15 African American adults with persistent asthma found five primary themes hindering inhaled corticosteroid (IC) use, including reluctance, social distractions and misconceptions about side effects. Improving communication between healthcare providers and patients is crucial to overcoming these barriers.
A possible predictor of tamoxifen resistance has been identified in a University of Illinois Chicago study. High levels of protein kinase C alpha may indicate reduced effectiveness of the drug, and researchers hope to develop more effective strategies for treating cancer recurrence.
Researchers have identified 46 new mutations in colon cancer genes that can be targeted by drugs, affecting approximately 30% of colorectal cancers. The study used a forward-looking approach to screen the genes that produce tyrosine kinases, resulting in the discovery of novel mutations that spur colon cancer.
A Phase II study found that the DVd regimen showed a high response rate of 88%, with 12% achieving complete response. The treatment was well-tolerated, with the most common Grade 3 or 4 toxicity being palmar-plantar erythrodysesthesia. Improved patient education and prevention measures reduced toxicity incidence.
A new study suggests that colonoscopy is more cost-effective in preventing colon cancer than promising Cox-II drugs. The study found that screening plus drugs was most effective but also the most costly option.
A new contrast agent has been shown to be 92% accurate in identifying malignant disease using MR imaging, outperforming CT scans in diagnosing testicular cancer metastases. The agent enhances lymph node signal intensity, allowing for earlier detection of disease.
Researchers at Cardiff University have discovered a gene, MBD2, essential for bowel cancer cells to grow but dispensable in normal cells. This finding suggests that drugs targeting MBD2 could prevent human bowel cancer without harming normal cells.
Researchers at Emory University Health Sciences Center identified a critical molecular link between estrogen receptors and invasive growth in breast cancer. The study reveals that a protein called MTA3 regulates cell adhesion molecule E-cadherin expression, leading to cancer progression.
A study demonstrated that low-dose tamoxifen can maintain clinical effect against breast cancer, reducing Ki-67 levels and tumor proliferation. The study found no dose response, suggesting that lower doses of the drug may be equally effective in treating ER-positive breast cancer.
Researchers at the University of Texas M. D. Anderson Cancer Center found that statin drugs can prevent breast cancer cells from growing by blocking proteins that inhibit cell cycle progression. The study suggests that potent anti-cancer drugs could be developed based on the unconverted form of statins.
Researchers found that celecoxib capsules stop the Sp1 transcription factor from activating genes associated with cancer growth. This led to reduced production of VEGF, a key angiogenic factor that feeds tumors. The study provides a novel molecular mechanism for celecoxib's antitumor activity and may lead to tailored treatment options.
According to a study by the National Cancer Institute, approximately 10 million women in the US aged 35-79 are eligible for tamoxifen due to high breast cancer risk. After analyzing age-related benefits and risks, researchers found that younger women (40-59) have a higher likelihood of benefiting from the drug.
According to a new study, nearly 10 million US women aged 35-79 could benefit from tamoxifen chemoprevention for breast cancer. White women are more likely to benefit than black or Hispanic women due to differences in risk factors and comorbidities.
Dr. Nie constructs smart nanoparticle probes to recognize DNA sequences and genetic mutations, enabling early cancer diagnosis and personalized medicine. The nanobeacons can profile multiple genes and proteins simultaneously, allowing for individualized cancer treatments based on molecular differences.
Researchers have developed a novel screening technique that quickly identifies chemical compounds active only against certain cancer-causing genes and proteins. This approach opens the door to custom-tailoring chemotherapy and may lead to more effective treatments for specific types of cancer.
Studies of hypereosinophilic syndrome reveal a novel mechanism for generating a cancer-causing tyrosine kinase. Gleevec treatment leads to extraordinary responses in patients, including complete recovery from severe organ damage.
Researchers at Dana-Farber Cancer Institute discover that a rare blood disorder HES is caused by a fusion of genes creating a cancer-causing gene, which can be inhibited by the imatinib drug. The study shows that patients with HES respond well to the treatment, offering new hope for this aggressive disease.
A study of over 339 patients found that 77% of those continuing Raptiva therapy had a PASI 50 score and 51% achieved a PASI 75 score. Long-term treatment showed improved response rates, with 22% achieving a 90% or greater improvement in their PSASI score.
Scientists at Whitehead Institute for Biomedical Research developed a screening strategy to identify mutations that cause cancer drug resistance. The study identified 112 mutations, including 15 previously linked to Gleevec resistance, and created a 3D computer model to visualize their location on the BCR/ABL protein.
A recent study published in the New England Journal of Medicine reveals that two types of medications used to treat osteoporosis and certain cancers can cause inflammation in the eyes, leading to vision loss or blindness if left untreated. The research found that almost 100 patients experienced blurred vision, pain, and swelling as a r...
This year's AACR honorees have made significant advances in understanding and treating cancer. The winners include Mario R. Capecchi, Ronald A. DePinho, Carlos L. Arteaga, Malcom F. Stevens, Martin J. Blaser, David S. Alberts, Graham A. Colditz, Janet D. Rowley, who will receive awards for their outstanding research in various areas of...
Charles J. Sherr and Dennis J. Slamon are being honored with the Landon-AACR Prizes for Cancer Research, recognizing their significant contributions to understanding mechanisms of cell growth control and developing targeted cancer therapies.
The new center at Dana-Farber will conduct therapeutic antibody research, providing high affinity human single-chain antibodies to support cancer research globally. Marasco's laboratory has constructed a large phage display library to quickly isolate antibodies against various cancer targets.
A study found that green and white tea can prevent colon tumors as effectively as the prescription drug sulindac. Moderate consumption of these teas may provide cancer protection without side effects associated with NSAIDs. The combination of tea and sulindac showed an 80% tumor reduction.
Researchers at Johns Hopkins Medicine discovered a primitive cellular pathway, Sonic Hedgehog, that stays active in some lung cancers. The pathway's activation leads to excessive cell growth and cancer. Researchers are testing drugs on mice and plan to explore human clinical trials in the future.
Researchers found that women with high levels of AIB1 and HER-2 proteins in their tumors are more likely to experience poor outcomes with tamoxifen therapy. When either protein level is low, the risk of adverse effects decreases significantly.
A Phase III randomized trial found that a combination of vinorelbine and gemcitabine did not improve overall and progression-free survival in elderly NSCLC patients. However, the study suggests that certain chemotherapy combinations, particularly cisplatin-based regimens, may be more effective than single-agent therapy. The results als...